SECTOR OF CARE VARIATIONS IN PRESCRIPTIONS OF SGLT2 INHIBITORS (SGLT2I) AND GLP-1 RECEPTOR AGONISTS (GLP-1 RA) IN THE US MILITARY HEALTH SYSTEM (MHS)

被引：0
|
作者：
Nguyen, Julia [1 ]
Nee, Robert [1 ,2 ]
Marneweck, Hava [3 ]
Banaag, Amanda [3 ]
Koehlmoos, Tracey [2 ]
Oliver, James [1 ,2 ]
机构：
[1] Walter Reed Natl Mil Med Ctr, Bethesda, MD 20814 USA
[2] Uniformed Serv Univ Hlth Sci, Bethesda, MD 20814 USA
[3] Henry M Jackson Fdn Advacement Mil Med Inc, Bethesda, MD 20817 USA
来源：
AMERICAN JOURNAL OF KIDNEY DISEASES | 2025年 / 85卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
G-371
引用
收藏
页数：2
相关论文
共 50 条
  • [31] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [32] Impact of Endocrine E-Consultation on SGLT2i and GLP-1 RA Prescription
    Rasheed, Amna
    Kompala, Tejaswi
    Neinstein, Aaron B.
    DIABETES, 2021, 70
  • [33] Combination therapy with GLP-1 receptor agonist and SGLT2 inhibitor
    DeFronzo, Ralph A.
    DIABETES OBESITY & METABOLISM, 2017, 19 (10): : 1353 - 1362
  • [34] Expected Health Benefits of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Older Adults
    Dadwani, Rahul S.
    Wan, Wen
    Skandari, M. Reza
    Huang, Elbert S.
    MDM POLICY & PRACTICE, 2023, 8 (02)
  • [35] SGLT2 Inhibitors vs. GLP-1 Agonists to Treat the Heart, the Kidneys and the Brain
    Rolek, Bartosz
    Haber, Mateusz
    Gajewska, Magdalena
    Rogula, Sylwester
    Pietrasik, Arkadiusz
    Gasecka, Aleksandra
    JOURNAL OF CARDIOVASCULAR DEVELOPMENT AND DISEASE, 2023, 10 (08)
  • [36] SGLT2 inhibitors vs. GLP-1 agonists: Comparative progression of renal disease
    Stevens, Lauren
    Bowe, Andy
    Schwab, Phil
    Tindal, Michael
    Bloomfield, Andrea
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2021, 30 : 110 - 110
  • [37] The Role of Industry and NIH/Academia in the Clinical Development of GLP-1 Agonists and SGLT2 Inhibitors
    Kocak, Brian R.
    Kassir, Zachary
    Luo, Jing
    DIABETES, 2021, 70
  • [38] SGLT2 inhibitor or GLP-1 receptor agonist in type 2 diabetes?
    Scheen, Andre J.
    LANCET DIABETES & ENDOCRINOLOGY, 2019, 7 (11): : 818 - 820
  • [39] The cardiovascular safety trials of DPP-4 inhibitors, GLP-1 agonists, and SGLT2 inhibitors
    Secrest, Matthew H.
    Udell, Jacob A.
    Filion, Kristian B.
    TRENDS IN CARDIOVASCULAR MEDICINE, 2017, 27 (03) : 194 - 202
  • [40] SGLT2 inhibitor/GLP-1 receptor agonists as first step monotherapy—evidence and implications
    Anil Pareek
    Ravi T. Mehta
    Shruti Dharmadhikari
    International Journal of Diabetes in Developing Countries, 2020, 40 : 636 - 637
12345